Header Logo

Connection

ARGUN AKCAKANAT to Antibodies, Bispecific

Back to Details
This is a "connection" page, showing publications ARGUN AKCAKANAT has written about Antibodies, Bispecific.
ARGUN AKCAKANAT
Connection Strength
0.175
Antibodies, Bispecific
  1. Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer Discov. 2024 May 01; 14(5):828-845.
    View in: PubMed
    Score: 0.175
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.